This Week in Cardiology

Aspirin for primary prevention, alcohol and Afib, high-sensitivity troponin, and women in interventional cardiology are discussed in this week's podcast.

Burnout, aspiration thrombectomy, fish intake, insurance coverage, and the gout drug febuxostat are discussed in this week's podcast.

Appropriate use criteria for imaging, HRRP efficacy, medical marijuana, radiation exposure in the cath lab, and hormone therapy are the topics discussed this week's podcast.

The cost of treating high blood pressure, heart-failure readmission policies, abdominal fat, low flow/low gradient aortic stenosis and hypertensive disorders of pregnancy are discussed this week.

Dr John Mandrola discusses upcoding for PCI, hypertension, a pacing lead issue, a PAD trial discovery, and an FDA warning on fluoroquinolones in this week's podcast.

Carotid stents, more stem-cell retractions, AHA statement on statin safety, flu vaccine rules, medication errors, veterans care, and wasteful NIH research on golfing are discussed in this week's podcast.

Measures of hospital quality, statin under- or over-use, Botox for AF, smoking cessation and translating trial evidence to clinical practice are discussed in this week's podcast.

TAVR vs surgery for high-risk aortic stenosis, conflicts of interest for physicians and societies, spin in the CV literature, and low-carb diets are discussed in this week's podcast.

The top 5 studies from the recent American Heart Association meeting and the new cholesterol guidelines are discussed in this week's podcast.

ODYSSEY PCSK9 inhibitor trial in print, new bradycardia guidelines, echocardiography, and an AHA preview are the topics discussed in this week's podcast.

CV outcomes in patients with type 2 diabetes, canagliflozin, cardiorespiratory fitness, the value of randomized trials, and the most important paper of 2018 are reviewed in this week's podcast.

Oxygen supplementation, PCSK9 inhibitor pricing, rapid troponin testing, cardio-oncology and joint commission accreditation are discussed in this week's podcast.

Low-dose rivaroxaban for CAD/PAD, hypertension management in the community, research misconduct, cyber-security in cardiac devices, and bariatric surgery are discussed in this week's podcast.

Timing of aortic valve replacement, rivaroxaban failure post TAVR, statins beyond CVD, conflicts of interest, and post-stent antithrombotic management are discussed in this week's podcast.

The COAPT MitraClip trial, high dose omega-3 fatty acids, the VEST trial in print, renal denervation for resistant hypertension, and competing coronary stents are discussed in this TCT-heavy podcast.

ASA, polypharmacy, statins and obesity treatments are the topics discussed by Dr John Mandrola in this week's podcast

The Apple Watch EKG, ablate/pace strategies, chronic total occlusion-PCI, assisted reproduction strategies and CV health, and remembering Ron Victor, MD are the topics for this week's podcast.

High sensitivity troponin, radial access (a good news story!), stroke care, rivaroxaban in CAD and PAD, and the components of a healthy diet are discussed in this week's podcast.

The salt wars, drug costs and vaule, Takotsubo syndrome, carb intake, and the upcoming European Society of Cardiology congress are discussed in this week's podcast

Screening athletes, AF ablation complications, physician gender and MI mortality, the rise of chronic kidney disease, and the rosuvastatin lawsuit are discussed in this week's podcast.

AF screening, atrial flutter, palliative care in heart failure, and LDL-C lowering are discussed in this week's podcast

Aspirin dosing, a potential new drug for SVT, apixaban in patients with ESRD, TAVR, and saunas, are discussed in this week's podcast

Leadless pacing, AF detection, coronary calcium, BP control and omega-3 fatty acids are discussed in this week's podcast.

Questionable ICD use, ambulatory blood pressure monitoring, multivitamins and cardiovascular health, and end-of-life care are discussed in this week's podcast